Amiodarone Therapy

Introduction to Amiodarone

Amiodarone is a well-documented photosensitizer that causes photosensitivity reactions in more than 50% of treated patients, and the American College of Cardiology recommends that patients taking amiodarone should be advised to seek shade when outside, particularly around midday, wear protective clothing, use broad-brimmed hats and sunglasses, and apply broad-spectrum sunscreens with SPF 30 or higher 1

The typical presentation of amiodarone-induced photosensitivity includes burning and tingling sensation in sun-exposed skin, associated erythema, and develops shortly after sun exposure 1
Amiodarone can cause several adverse effects, including thyroid dysfunction (hypothyroidism and hyperthyroidism), pulmonary toxicity, gastrointestinal effects, ophthalmologic effects, and dermatologic effects 2

Patients taking amiodarone should be counseled about photosensitivity risk before starting the medication, and regular skin examinations should be included in routine follow-up 1
If severe photosensitivity occurs, consider dose reduction if clinically feasible, or alternative anti-arrhythmic agents if the patient's cardiac condition allows 1
The American Academy of Family Physicians recommends using the lowest effective dose to minimize the risk of hepatotoxicity, with monitoring compliance often being suboptimal, and a comprehensive approach to monitoring all potential amiodarone toxicities being necessary for safe long-term management 2
Patients should be advised on sun protection, including the use of high-SPF sunblock and covering exposed skin when outdoors, and regular skin examinations should be included in routine follow-up 2

Photosensitivity can occur even with brief sun exposure and may be exacerbated by factors such as altitude, reflective surfaces, and time of day 1
Pre-existing hepatic dysfunction, hepatic congestion due to heart failure, low ejection fraction, high daily doses, prolonged duration of therapy, and concomitant use of other hepatotoxic medications may increase the risk of hepatotoxicity 2

The American Academy of Family Physicians recommends regular monitoring of liver transaminase levels every six months in patients on long-term amiodarone therapy, as liver toxicity occurs at a rate of 0.6% annually, with asymptomatic elevation of liver transaminases being the most common hepatic manifestation 2
Liver transaminase levels should be checked every 6 months during maintenance therapy, with more frequent monitoring necessary in patients with pre-existing liver disease or those showing signs of hepatotoxicity, and consideration of discontinuation if liver enzyme levels exceed three times normal values 2
Regular monitoring is essential for early detection of toxicity, with the frequency of most adverse effects relating to total amiodarone exposure (dosage and duration) 2
Discontinuation of amiodarone may be necessary if liver enzyme levels exceed three times normal values or clinical symptoms of liver dysfunction develop, unless the patient is at high risk for recurrence of life-threatening arrhythmias 2